Increase in cases of breast cancer boost R&D

(PRWEB) November 6, 2003 --In Europe and the US there are close to 20 million people that live with cancer today, a figure that is increasing. 6.2 million people worldwide died of cancer in 1998. The American Cancer Society estimates that approximately 1.2 million new cancer cases were diagnosed in the year 2000 in the US. Overall annual costs associated with cancer currently amount to $107 billion in the United States alone. The worldwide anti-cancer market was valued at more than $15 billion in 1998 and is projected to nearly double by 2003. Approximately 30% of all collaborative deals are signed in the field of cancer.

There are several types of breast cancer. The most common is ductal carcinoma, which begins in the lining of the milk ducts of the breast. Another type, lobular carcinoma, begins in the lobules where breast milk is produced. If a malignant tumor invades nearby tissue, it is known as infiltrating or invasive cancer. Therapeutic decisions are formulated in part according to staging categories but primarily according to tumor size, lymph node status, estrogen- and progesterone-receptor levels in the tumor tissue, menopausal status, and the general health of the patient.

One in 8 women in the United States (approximately 13.3 percent) will develop breast cancer during her lifetime (NCI). According to CDC, the incidence of invasive breast cancer has shown a small increase during the last 30 years, probably due to an increasingly aged population. Even with an increasing incidence, the mortality rate has dropped slightly during the last 10-15 years. The most dramatic decrease is seen in younger patients (<50 years).

The Global Structure of Breast Cancer R&D is one of the most comprehensive and up to date information sources currently available in the breast cancer R&D arena. Information about new innovative cancer therapies such as antisense, monoclonal antibodies, gene therapy, antigen- or cellular-based vaccines, liposomal hormones and apoptotic drugs are analyzed in more than 100 extensive tables and graphs. This report will give you easy-to-read tables with projects classified into well-defined structures based on type of therapy given, effect and mechanism. The graphs provide all the relations of these factors as well as the general and specific trends in the current breast cancer pipeline.

This report is designed to give:

1. Information on more that 180 companies active in breast cancer R&D
2. Information on more that 380 industry related breast cancer projects
3. Data from 198 clinical trials
4. Information on more than 140 preclinical projects
105 graphs illustrating the most important relations between types of therapy,
effects and mechanisms
5. Advanced analysis of general and specific trends in the pipeline
6. The data has been structured as follows:

Therapy Given - such as Antisense, Biological drug, Cell therapy, Monoclonal antibody, or Small molecular drug etc. Therapeutic Effect - such as Antiangiogenesis, Immunotherapy, Apoptosis, Cytotoxic, Growth Inhibition, or Vascular Targeting etc. Mechanism of Action - such as Estrogen modulation, Cell-cycle inhibition, targeting of Bcl-2 or p53, VEGF or EGF Antagonist, or TumorAntigen etc.

For a complete index of this report click on
http://www.researchandmarkets.com/reports/39361

About Research and Markets Ltd.
Research and Markets Ltd. are Europe's largest resource for market research. R&M distribute thousands of major research publications from the world's leading publishers, consultants and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends.

For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com or
mailto:press@researchandmarkets.com
###